NCT01239108View on ClinicalTrials.gov

Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Relapsed/Refractory Leukemias
Interventions
DRUG

SGI-1776

SGI-1776 will be administered orally at escalating dose levels ranging from 350 to 1600 mg/day based on the dose escalation levels of the ongoing, first-in-human study.

Trial Locations (1)

Unknown

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Astex Pharmaceuticals, Inc.

INDUSTRY